Article Versions Notes

Vall-Sagarra A, Litau S, Decristoforo C, Wängler B, Schirrmacher R, Fricker G, Wängler C. Design, Synthesis, In Vitro, and Initial In Vivo Evaluation of Heterobivalent Peptidic Ligands Targeting Both NPY(Y₁)- and GRP-Receptors—An Improvement for Breast Cancer Imaging? Pharmaceuticals. 2018; 11(3):65. https://doi.org/10.3390/ph11030065

Vall-Sagarra, Alicia, Shanna Litau, Clemens Decristoforo, Björn Wängler, Ralf Schirrmacher, Gert Fricker, and Carmen Wängler. 2018. "Design, Synthesis, In Vitro, and Initial In Vivo Evaluation of Heterobivalent Peptidic Ligands Targeting Both NPY(Y₁)- and GRP-Receptors—An Improvement for Breast Cancer Imaging?" Pharmaceuticals 11, no. 3: 65. https://doi.org/10.3390/ph11030065

Vall-Sagarra, A., Litau, S., Decristoforo, C., Wängler, B., Schirrmacher, R., Fricker, G., & Wängler, C. (2018). Design, Synthesis, In Vitro, and Initial In Vivo Evaluation of Heterobivalent Peptidic Ligands Targeting Both NPY(Y₁)- and GRP-Receptors—An Improvement for Breast Cancer Imaging? Pharmaceuticals, 11(3), 65. https://doi.org/10.3390/ph11030065